DDInter948 DDInter1891
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens.
Tucatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Tucatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Quinine
Tucatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Tucatinib {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Tucatinib {u} may lead to a major life threatening interaction when taken with {v} Olaparib
Tucatinib may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Quinine
Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Tucatinib may lead to a major life threatening interaction when taken with Ribociclib
Tucatinib may lead to a major life threatening interaction when taken with Olaparib